• Philip Morris International recently announced that the U.S. FDA granted Modified Risk Tobacco Product orders for 20 ZYN nicotine pouch variants, allowing them to be marketed in the U.S. as a lower-risk alternative to cigarettes for several serious diseases.
• This is the first time nicotine pouches have received MRTP status, giving ZYN a unique, FDA-authorized health-risk claim that could materially differentiate it from competing oral nicotine products.
• Next, we’ll examine how this first-of-its-kind FDA modified-risk approval for ZYN could reshape Philip Morris International’s smoke-free investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.

Philip Morris International Investment Narrative Recap

To own Philip Morris International, you need to believe its shift from cigarettes to smoke free products can support earnings even as combustibles decline and regulation stays tough. The new FDA modified risk orders for 20 ZYN variants reinforce that smoke free narrative, but they do not remove the key near term risk that growth in ZYN and IQOS could slow or fail to offset ongoing pressure in traditional tobacco.

The recent leadership changes, including new regional presidents for Europe and Latin America & Canada, matter here because execution in regulated markets will shape how effectively PMI converts this ZYN MRTP milestone into sustained smoke free adoption, while also managing risks from illicit trade, taxation and possible moderation in alternative nicotine growth.

Yet behind the positive ZYN headlines, investors still need to think carefully about the risk that smoke free growth could slow just as...

Philip Morris International's narrative projects $49.6 billion revenue and $15.3 billion earnings by 2029. This requires 6.1% yearly revenue growth and about a $4.2 billion earnings increase from $11.1 billion today.

Uncover how Philip Morris International's forecasts yield a $193.14 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenues of about US$54.0 billion and earnings near US$16.2 billion by 2029, so you should recognize that their view of ZYN and smoke free momentum is far more optimistic than the baseline narrative and could shift again after this FDA decision.

Explore 9 other fair value estimates on Philip Morris International - why the stock might be worth 10% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Philip Morris International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Philip Morris International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Philip Morris International's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 43 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.